Muul LM - Search Results

1

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH. Ram Z, et al. Among authors: muul lm. Nat Med. 1997 Dec;3(12):1354-61. doi: 10.1038/nm1297-1354. Nat Med. 1997. PMID: 9396605 Clinical Trial.

2

High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA. Bunnell BA, et al. Among authors: muul lm. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7739-43. doi: 10.1073/pnas.92.17.7739. Proc Natl Acad Sci U S A. 1995. PMID: 7644487 Free PMC article.

3

Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy.

Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Tuschong L, et al. Among authors: muul lm. Hum Gene Ther. 2002 Sep 1;13(13):1605-10. doi: 10.1089/10430340260201699. Hum Gene Ther. 2002. PMID: 12228015

4

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. Blaese RM, et al. Science. 1995 Oct 20;270(5235):475-80. doi: 10.1126/science.270.5235.475. Science. 1995. PMID: 7570001 Clinical Trial.

5

Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults.

Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT Jr, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC. Walker RE, et al. Nat Med. 1998 Jul;4(7):852-6. doi: 10.1038/nm0798-852. Nat Med. 1998. PMID: 9662381

6

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F. Muul LM, et al. Blood. 2003 Apr 1;101(7):2563-9. doi: 10.1182/blood-2002-09-2800. Epub 2002 Nov 27. Blood. 2003. PMID: 12456496 Free article. Clinical Trial.

7

T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R. Kohn DB, et al. Nat Med. 1998 Jul;4(7):775-80. doi: 10.1038/nm0798-775. Nat Med. 1998. PMID: 9662367 Free PMC article.

8

Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB. Candotti F, et al. Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11. Blood. 2012. PMID: 22968453 Free PMC article. Clinical Trial.

9

Morphology of interleukin-2-stimulated human peripheral blood mononuclear effector cells killing glioma-derived tumor cells in vitro.

Hook GR, Greenwood MA, Barba D, Ikejiri B, Chen SN, Oldfield EH, Weber RJ, Muul LM. Hook GR, et al. Among authors: muul lm. J Natl Cancer Inst. 1988 Apr 6;80(3):171-7. doi: 10.1093/jnci/80.3.171. J Natl Cancer Inst. 1988. PMID: 3258038

10

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.

Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC. Morgan RA, et al. Hum Gene Ther. 2005 Sep;16(9):1065-74. doi: 10.1089/hum.2005.16.1065. Hum Gene Ther. 2005. PMID: 16149905

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters